Astellas Pharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Astellas Pharma generated cash of $172,475,000,000, which is less than the previous year. Cash used in financing activities reached the amount of $614,060,000,000 last year. Net change in cash is therefore -$41,153,000,000.
Cash Flow
| 2015 | 187.68B | -71.47B | -121.11B |
|---|---|---|---|
| 2016 | 316.53B | -149.84B | -193.47B |
| 2017 | 237.23B | -75.00B | -166.15B |
| 2018 | 314.46B | -123.64B | -203.42B |
| 2019 | 261.42B | -44.55B | -233.68B |
| 2020 | 224.06B | -391.85B | 181.05B |
| 2021 | 307.88B | -82.93B | -229.47B |
| 2022 | 258.16B | -63.12B | -216.29B |
| 2023 | 332.32B | -89.05B | -195.62B |
| 2024 | 172.47B | -845.80B | 614.06B |
ALPMY Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 376.84B | 315.98B | 326.12B | 318.39B | 311.07B | 331.73B | 340.92B | 360.03B | 396.43B | 0 |
Operating activities | ||||||||||
Net income | 17.04B | 98.71B | 124.08B | 120.58B | 195.41B | 222.26B | 164.67B | 218.70B | 193.68B | 135.85B |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 157.84B | 105.73B | 79.68B | 72.65B | 66.39B | 63.45B | 64.86B | 63.79B | 69.18B | 65.47B |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -55.94B | -4.84B | -8.00B | 22.16B | -16.39B | -25.64B | -6.63B | 5.05B | -15.64B | 3.91B |
Inventories | -60.03B | -7.08B | 24.05B | -2.31B | -6.03B | -5.48B | 37.83B | -26.64B | -11.87B | -18.15B |
Accounts payable | 29.46B | -12.27B | -10.10B | -51.56B | -21.36B | 40.82B | -43.80B | 15.65B | -32.39B | 0 |
Cash generated by operating activities | 172.47B | 332.32B | 258.16B | 307.88B | 224.06B | 261.42B | 314.46B | 237.23B | 316.53B | 187.68B |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | -5.57B | 0 | 0 | 0 | -693M | -484M | -749M | 0 |
Investments In Property Plant And Equipment | -38.05B | -88.54B | -76.44B | -77.44B | -77.88B | -52.12B | -40.28B | -48.64B | -118.11B | -24.15B |
Acquisitions Net | -784.97B | 0 | -229M | -8.08B | -313.84B | 1.65B | -82.51B | -49.65B | -40.9B | 0 |
Cash generated by investing activities | -845.80B | -89.05B | -63.12B | -82.93B | -391.85B | -44.55B | -123.64B | -75.00B | -149.84B | -71.47B |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | -17.66B | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | -116.65B | -100.35B | -85.23B | -76.15B | -73.53B | -72.06B | -71.63B | -70.11B | -69.61B | -62.14B |
Repurchases of common stock | -10.73B | -60.55B | -50.71B | -9.16B | -52.89B | -160.44B | -130.71B | -92.19B | -120.12B | -58.22B |
Repayments of term debt | 771.23B | -15B | -60B | -126B | -326B | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 614.06B | -195.62B | -216.29B | -229.47B | 181.05B | -233.68B | -203.42B | -166.15B | -193.47B | -121.11B |
Net Change In Cash | -41.15B | 60.85B | -10.14B | 7.73B | 7.31B | -20.65B | -9.19B | -19.10B | -36.4B | 5.05B |
Cash at end of period | 335.68B | 376.84B | 315.98B | 326.12B | 318.39B | 311.07B | 331.73B | 340.92B | 360.03B | 5.05B |